Keros Therapeutics (NASDAQ:KROS) Shares Down 2.7% on Analyst Downgrade

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) dropped 2.7% on Tuesday after Truist Financial lowered their price target on the stock from $100.00 to $43.00. Truist Financial currently has a buy rating on the stock. Keros Therapeutics traded as low as $16.63 and last traded at $16.65. Approximately 211,223 shares changed hands during trading, a decline of 57% from the average daily volume of 487,966 shares. The stock had previously closed at $17.12.

KROS has been the topic of several other research reports. Wells Fargo & Company boosted their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. HC Wainwright cut their target price on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Finally, Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. KBC Group NV lifted its holdings in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics during the 3rd quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics during the 2nd quarter valued at approximately $128,000. Finally, LMR Partners LLP purchased a new stake in shares of Keros Therapeutics during the 3rd quarter worth approximately $213,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Down 2.4 %

The business’s fifty day moving average is $54.10 and its two-hundred day moving average is $51.40. The stock has a market capitalization of $676.87 million, a PE ratio of -3.21 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.33) earnings per share. Sell-side analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.